DB18577InvestigationalCell transplant therapies
TRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.
- Also known as
- Natural Regulatory T Cells (T-Regs), Expanded with Interleukin-2, ExpAct Beads (CD3/CD28; Miltenyi), Rapamycin and Transforming Growth Factor-beta
- Code names
- TRK-001
What you can answer from here — as of April 23, 2025
Which companies are running trials of TRK-001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account